HCW 9213
Alternative Names: HCW-9213Latest Information Update: 23 Jun 2022
At a glance
- Originator HCW Biologics
- Class Anti-inflammatories; Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Inflammation